ClinicalTrials.gg
RecruitingNCT06938321Updated Mar 3, 2026

A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer

A Phase 1/2 interventional study of AK112 and AK130 in Biliary Tract Cancer, sponsored by Akeso. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Akeso · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies in Biliary Tract Neoplasms with a site in China — 93 open to participants now, 111 under way, 11 of them phase 3. Biliary Tract Neoplasms · China.

Planned enrollment
41st of 157
135 · median 62
Started
2025
with 23 others
Phase 1/2
24 of 176
11 open now
Primary completion
2027-05
later than 52 of 110 live
Registered
120th of 176
by date

Among the 176 studies in Biliary Tract Neoplasms with a site in China, this one is the 41st largest by planned enrollment of the 157 interventional ones that give a count, is one of 24 that started in 2025, is one of 24 in phase 1/2, reaches primary completion later than 52 of the 110 other live ones, and was the 120th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

93 of the 176 studies in Biliary Tract Neoplasms with a site in China are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 141 Biliary Tract Neoplasms studies recruiting now, 81 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies in Biliary Tract Neoplasms with a site in China, or all of them as a file.
02

Study summary

There're 2 parts in this interventional study:

  1. The goal of phase Ib trial is to evaluate the safety and tolerability of AK130 in combination with AK112 therapy for the purpose of observing the incidence of dose limit toxicity (DLT) as well as the confirmation of maximum tolerable dose (MTD) in the treatment of advanced biliary tract cancer (BTC), so as to determine the recommended phase 2 dose (RP2D) in the second part of the trial.
  2. The goal of phase II trial is to evaluate the safety and efficacy of AK112 in combination with AK130 therapy or monotherapy in the treatment of advanced BTC.
03

Conditions studied

  • Biliary Tract Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be able and willing to provide written .
  2. Have a of at least 3 months.
  3. Have an (ECOG) performance status of 0 or 1.
  4. Subjects with and/or cytologically confirmed advanced or biliary tract (including only intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder carcinoma; excluding ampullary carcinoma), who have experienced treatment failure following prior systemic therapy.
  5. According to v1.1, there is at least one untreatable , or a measurable lesion with clear imaging progression after local treatment, suitable for repeated and accurate measurement.
  6. Has adequate organ function.
  7. All subjects of must agree to use an effective method of , as determined by the Investigator, during and for 120 days after the last dose of study treatment.
  8. Able to to comply with all requirements of study participation (including all study procedures).

Exclusion criteria

Exclusion Criteria:

  1. Except for BTC, the subjects had other malignant tumors within the 3 years prior to enrollment. Subjects with other malignant tumors that have been cured through local treatment are not excluded, such as basal or cutaneous squamous cell carcinoma, superficial bladder cancer, cervical or breast cancer in situ.
  2. There is central nervous system (CNS) , spinal cord compression, or meningeal metastasis.
  3. There are pleural effusion, pericardial effusion, or ascites with clinical symptoms or requiring repeated drainage.
  4. Prior administration of any immunotherapy targeting immune mechanisms other than /PD-L1 inhibitors.
  5. There is a history of non infectious pneumonia that requires systemic treatment.
  6. History of severe bleeding tendency or coagulation dysfunction.
  7. Previous history of myocarditis, cardiomyopathy, and malignant arrhythmia.
  8. Any arterial or severe venous thromboembolism events, , cerebrovascular accidents, hypertensive crises, or hypertensive encephalopathy occurred within 6 months prior to the first administration of medication.
  9. Pregnant or lactating female subject.
  10. Any prior or concurrent disease, treatment, or laboratory test abnormality that may confuse study results, affect subjects' full participation in the study, or may not be in their best interest to participate.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
135 participants (estimated)

Study arms

  • Experimental
    AK112 in combination with AK130

    Drug: AK112 · Drug: AK130

  • Experimental
    AK112

    Drug: AK112

Interventions

  • DrugAK112

    Following a predefined dose and date.

  • DrugAK130

    Following a predefined dose and date.

06

What researchers measure

Primary outcomes

  1. Number of subjects with dose limiting toxicities (DLTs)

    DLTs will be assessed during the first three weeks of treatment. DLTs are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the DLT observation period.

    Time frame: During the first three weeks.

  2. Number of subjects with adverse events (AEs)

    AE refers to any untoward medical occurrence or deterioration of existing medical event after the subject signed the ICF, whether or not considered related to the study treatment.

    Time frame: From the time of informed consent signed through 30 days after the last dose of study drug or starting new anti-cancer therapy.

  3. Objective Response Rate (ORR) (Phase II)

    ORR is defined as the proportion of subjects with BOR response of CR or PR (based on RECIST Version 1.1).

    Time frame: Through study completion, an average of 2 years.

Secondary outcomes

  1. Objective Response Rate (ORR) (Phase Ib)

    ORR is defined as the proportion of subjects with BOR response of CR or PR (based on RECIST Version 1.1).

    Time frame: Through study completion, an average of 2 years.

  2. Disease control rate (DCR)

    DCR is defined as the proportion of subjects with response of CR, PR and SD (based on RECIST Version 1.1).

    Time frame: Through study completion, an average of 2 years

  3. Duration of Response (DoR)

    The time from first documented evidence of CR or PR until time of first documented disease progression.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

  4. Time to response (TTR)

    Time between date of start of treatment until first documented response (CR or PR).

    Time frame: From date of randomization until the date of first documented response, assessed up to 24 months

  5. Progression Free Survival (PFS)

    PFS is defined as the interval between first dose and the earliest date of disease progression or death due to any cause.

    Time frame: Through study completion, an average of 2 years.

  6. Overall survival (OS)

    OS is defined as the time from first dose until death due to any cause

    Time frame: Through study completion, an average of 2 years.

07

Study locations

1 of 1 sites recruiting
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality, China
    Recruiting
    • Haitao Zhao · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for May 2027, 25 months after the start.

Of 48 phase 1/2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 68. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Apr 22, 2025
StartActual
Apr 30, 2025
Primary completionEst.
May 2027
CompletionEst.
Dec 2027
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06938321
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Apr 22, 2025
Start date
Apr 30, 2025
Primary completion
May 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 3, 2026

Study contacts

Wenting Li
Contact
wenting01.li@akesobio.com
18116403289

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivonescimab

Start the discussion